This paper discusses the mechanisms and need for exact biomarkers for the early diagnosis of chemotherapy-induced cardiotoxicity.
Absence of validated biomarkers for chemotherapy cardiotoxicity leaves open early detection strategies; hypothesis-generating pending larger studies.
A cardiotoxicity is a considerable event for cardiologists and oncologists during and after chemotherapy. The use of certain chemotherapy agents such as trastuzumab, programmed death-1 inhibitors, and Doxorubicin increased in cancer therapy; however, these agents associate with an increase in mortality and cardiotoxicity. Detecting cardiotoxicity is based on patient's medical history and physical examination since there is no exact biomarker or polymorphism for its early diagnosis. Therefore, we
No takes yet. Share an insight, caveat, or question.
Zayeri et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: